THROMBIN INHIBITOR MARKET ANALYSIS

Market Challenges And Opportunities

Thrombin Inhibitor Market Drivers:

1. Increasing prevalence of thrombosis-related disorders: Thrombosis-related disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), are a significant public health problem globally, with a high incidence in the elderly population. The increasing prevalence of these disorders is driving the demand for anticoagulant therapies, thus boosting the growth of the Thrombin Inhibitor Market. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC) in June 28, 2023, 900,000 people are affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) globally. Moreover, 33% among people who have had a DVT, one third to one half will have long-term complications such as swelling, pain, discoloration, and scaling in the affected limb.
2. Growing awareness programs about thrombosis-related disorders: The growing awareness programs about thrombosis-related disorders among healthcare providers and the general public is expected to drive the market growth over the forecast period. For instance, the International Society on Thrombosis and Hemostasis (ISTH) on October 23, 2023 created the world thrombosis day campaign to bring awareness against the deadly disease.

Thrombin Inhibitor Market Opportunities:

1. Increasing Product Launches by the Market Players: The market players are focusing on launching new products in the market to increase their market share, which is expected to propel the market growth over the forecast period. For instance, on July 18, 2023, Endo International plc, a pharmaceutical company, executed agreements with MAIA Pharmaceuticals, Inc., a pharmaceutical company and Gland Pharma Limited, a pharmaceutical company based in India to commercialize ready-to-use bivalirudin in the U.S. The product, manufactured by Gland Pharma Limited, is an anticoagulant (thrombin inhibitor) that helps prevent the formation of blood clots.
2. Development of new anticoagulant therapies: The development of new anticoagulant therapies with improved efficacy and safety profiles presents an opportunity for market players to capture a larger market share and meet the unmet medical needs of patients. For instance, on June 1, 2023, Sirnaomics Ltd., a biotechnology company, announced that it had dosed the first participant in a phase 1 clinical trial of STP122G for anticoagulation treatment.

Thrombin Inhibitor Market Restraints:

1. Increasing Product Recalls: Increasing product recalls by the market players due to adverse effects is expected to hinder the market growth over the forecast period. For instance, on March 23, 2023, Ascend Laboratories, a pharmaceutical company, issued a voluntary recall of 10 lots of the anticoagulants dabigatran etcxilate in capsule form after finding higher than acceptable levels of the suspected carcinogen N-nitroso-dabigatran during routine testing.
2. Stringent regulatory requirements: The regulatory requirements for the approval of anticoagulant therapies can be stringent and time-consuming, which can hinder the introduction of new products and limit the growth of the thrombin inhibitor market.